A leading international consultant haematologist in the treatment of multiple myeloma, Professor Saad Z. Usmani, Chief of Plasma Cell Disorders Program and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute and Carolinas HealthCare System in Charlotte, US, believes the results of the combined analysis from the SIRIUS and the GEN5011 trials on the use of the anti CD38 monoclonal antibody, Darzalex (daratumumab), are very exciting for the myeloma community.
Read more at:Â https://www.imt.ie/clinical/exciting-treatment-multiple-myeloma-community-15-11-2018/